Catalyze Group’s Post

🌍 Kexing Biopharm Partners with Qingfeng Pharma to Bring Olaparib Tablets to Global Markets!  💪 Olaparib Tablets, as a poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor, were initially indicated for BRCA-mutated advanced ovarian cancer, and subsequently expanded to ovarian cancer, breast cancer, pancreatic cancer, prostate cancer and other malignancies. It is a first-line therapeutic agent for breast cancer and a first-line maintenance therapy for ovarian cancer recommended by the NCCN clinical guidelines. 🎗️ #Breast and ovarian cancers are prevalent worldwide, with a booming market expected to surpass USD 50 billion. The addition of Olaparib underscores our dedication to providing comprehensive solutions for #breastcancer globally. #GlobalHealth #CancerTreatment #Innovation #KexingBiopharm #Olaparib

Bayer announced that its Phase 3 clinical ARANOTE trial met its primary endpoint. Its oral androgen receptor inhibitor (ARi) NUBEQA® (darolutamide) combined with androgen deprivation therapy (ADT) significantly improved radiographic progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC). NUBEQA® (darolutamide) is an oral androgen receptor inhibitor with a distinct chemical structure that binds to androgen receptors with high affinity and exhibits strong antagonistic activity, thereby inhibiting receptor function and the growth of prostate cancer cells. Chemenu has been working to develop more compounds for drug discovery. Here come the building blocks we can provide: https://lnkd.in/gjqHGjDw # Darolutamide # NUBEQA # AR # ADT # mHSPC # Chemenu # building blocks

🎉 IDEAYA Biosciences and Biocytogen Advance Cancer Therapy with IDE034 Bispecific ADC! IDEAYA Biosciences is licensing Biocytogen’s B7H3/PTK7 bispecific antibody-drug conjugate (ADC), IDE034, as part of a $406.5M deal. This first-in-class ADC shows promising monotherapy results for cancers like lung and colorectal and offers a potential for combination with IDEAYA's existing drugs. IDE034, developed on Biocytogen's RenLite platform, aims for clinical trials by 2025, targeting dual antigens co-expressed in solid tumors. #OncologyInnovation #CancerTherapy #BiotechPartnership #ADC #DrugDevelopment #LifeSciences

𝗖𝗿𝗶𝘁𝗶𝗰𝗮𝗹 𝗺𝗲𝗱𝗶𝗮𝘁𝗼𝗿 𝗼𝗳 𝗹𝘂𝗻𝗴 𝗰𝗮𝗻𝗰𝗲𝗿 𝗿𝗲𝘀𝗶𝘀𝘁𝗮𝗻𝗰𝗲 𝗶𝗱𝗲𝗻𝘁𝗶𝗳𝗶𝗲𝗱! Lung cancer is the primary cause of cancer-related deaths globally, accounting for one-third of all cancer deaths. The EGF receptor plays a crucial role in driving lung cancer, but targeted therapies often result in drug resistance. A recent study that used our TRC research chemicals (TRC-M325750) identified a critical mediator of lung cancer drug resistance. Read the findings in the journal Oncogene: https://okt.to/TZj2rO Our extensive cancer portfolio can help from target identification to drug development and generics manufacturing. Explore now: https://okt.to/sdm9ef #LungCancer #oncology #oncologyresearch #ResearchChemicals

Did you know? #Therapeutics for #oncology often work for some time until inevitably resistance to the drug develops. The #cancer then comes back often in a much more aggressive manner. Scientists at Kairos Pharma have discovered a central mechanism responsible for the development of cancer drug resistance. As patients are treated with Xtandi, Zytiga, or Erleada or other anti-androgen drugs for prostate cancer or with Tagrisso, Tarceva, or Iressa for lung cancer, the cancer starts making a protein called CD105 on the cancer cell surface which makes the cancer resistant to those drugs. Our drug ENV105 is an antibody that reverses the effect of CD105, rendering the cancer responsive to those drugs again. NYSE: KAPA #KairosPharma #CancerTreatment #HealthcareInnovation #BioTech #PharmaTech #BioTechStock #PharmaStock #NYSE

✨ Exciting developments and latest breakthroughs in oncology seen at #ESMO2024 This year’s ESMO Congress was the largest yet, with 33,336 attendees, 4,580 abstracts, and around 600 expert speakers in Barcelona. Companies like NiKang and JNJ showcased groundbreaking advancements in oncology, from a HIF-2α inhibitor for renal carcinoma to innovative bladder cancer treatments, marking significant progress in cancer therapy. These advances are shifting the focus from one-size-fits-all treatments to personalized therapies targeting specific mutations. Immunotherapies and CAR-T therapies are also offering new hope for patients. Comment below 👇 if you want more details of these readouts. Feel free to reach out at 📥 info@atacana.com if you'd like to learn more about the exciting developments in oncology or explore Atacana’s innovative solutions. #ESMO2024 #Oncology #Pharma #ClinicalResearch #Biotech #Investors #HealthcareInnovation #CancerResearch #NiKang #JohnsonandJohnson #Incyte #Amgen

🗞 Partnering News! 🗞 We are thrilled to annouce today the expansion of lead compound #roginolisib's clinical trial program to non-small-cell lung cancer (#NSCLC) 💊 Via new partnerships with GSK and ETOP IBCSG Partners Foundation, the study will investigate #dostarlimab + roginolisib +/- docetaxel in patients with NSCLC resistant to first-line checkpoint inhibitor therapy Combining #PI3Kδ inhibitor roginolisib with dostarlimab, a programmed death receptor-1 (PD-1) targeting agent, may prevent or reverse drug resistance in NSCLC 🏥 Further details on the randomized Phase II study will be released soon. 👉 Read the full press release here: https://lnkd.in/eJWN6cW3

📢New article alert from the Journal of Comparative Effectiveness Research:   Title: Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US   New research from Hernandez et al. compares adverse event management costs for fruquintinib, regorafenib, trifluridine/tipiracil (T/T), and T/T+bevacizumab for metastatic colorectal cancer patients previously treated with at least two prior lines of therapy. The article provides valuable insights for treatment, formulary and pathway decisions.   Authors: Victoria Federico Paly, N. Arvind Dasari, Joleen Hubbard, Tanios Bekaii-Saab, Thihan P. & Luis Hernandez Takeda Oncology, MD Anderson Cancer Center, Mayo Clinic   #Oncology #HealthEconomics #mCRC #PharmaResearch #OpenAccess   Link in the comments!

Zai Lab (NASDAQ: ZLAB, SEHK: 9688), a portfolio company of Qiming Venture Partners, announced that the first prescription of AUGTYRO® (repotrectinib) in China has been issued, providing a new treatment option for patients with ROS1-positive advanced non-small cell lung cancer (NSCLC). AUGTYRO® was recently included in China's updated National Reimbursement Drug List (NRDL), effective January 1, 2025, increasing patient access to this innovative therapy. As a next-generation tyrosine kinase inhibitor (TKI), repotrectinib targets the ROS1 oncogene and features a unique compact macrocyclic structure. This design helps to overcome ROS1 resistance mutations, offering new hope for TKI-naive and TKI-pretreated patients with ROS1-positive advanced NSCLC. #NSCLC #CancerTreatment #PrecisionMedicine #HealthcareInnovation #Repotrectinib #ROS1 #TKI #QimingPortfolio #QimingHealthcare

𝐔𝐧𝐥𝐨𝐜𝐤𝐢𝐧𝐠 𝐍𝐞𝐰 𝐇𝐨𝐫𝐢𝐳𝐨𝐧𝐬 𝐢𝐧 𝐂𝐚𝐧𝐜𝐞𝐫 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭: 𝐓𝐡𝐞 𝐑𝐢𝐬𝐞 𝐨𝐟 𝐦𝐓𝐎𝐑 𝐈𝐧𝐡𝐢𝐛𝐢𝐭𝐨𝐫𝐬 The fight against cancer gets a boost with the mTOR inhibitor market poised for a significant leap! Custom Market Insights™ reports a projected CAGR of 4.8% for the mTOR Inhibitors market, reaching a value of USD 11,909.1 Million by 2033. This growth is driven by: ✔️Read More :https://lnkd.in/diCqWXbb - Increased adoption in oncology for various cancers - Promising advancements in transplantation medicine - A surge in clinical research exploring their efficacy Their report acts as your compass, guiding you through: ☛ Emerging applications of mTOR inhibitors beyond oncology ☛ The innovation pipeline with next-generation mTOR inhibitor development ☛ Strategies to navigate potential challenges like drug resistance Don't miss out on this groundbreaking market. Download Custom Market Insights' report and be at the forefront of the future of cancer treatment! Click Here-https://lnkd.in/daZH-X3m #mTORInhibitors #cancertreatment #oncology #medicalinnovation #CustomMarketInsights #mTOR #Inhibitors #cmi